Latest News and Press Releases

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder (Manic Depression)- Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers an extensive...

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective,...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of...

Dublin, April 10, 2025 (GLOBE NEWSWIRE) -- The "Mental Well-Being Supplements Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Mental Well-Being...

MINNEAPOLIS, March 19, 2025 (GLOBE NEWSWIRE) -- Major depression impacts more than 5 million U.S. adolescents every year, and NIH data shows that 20% of those aged 12 to 16 have had at least one...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate...

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is...

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients...

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...